ArticleTranslational psychiatry2016
AKT1 genotype moderates the acute psychotomimetic effects of naturalistically smoked cannabis in young cannabis smokers.
Article in Translational psychiatry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 103 citations in OpenAlex.
- Experimentally exploring the potential behavioral effects of personalized genetic information about marijuana and schizophrenia risk.Journal of psychiatric research · 2021Trial
- Highs and lows of cannabinoid-dopamine interactions: effects of genetic variability and pharmacological modulation of catechol-O-methyl transferase on the acute response to delta-9-tetrahydrocannabinol in humans.Psychopharmacology · 2019Trial
- Individual and combined effects of acute delta-9-tetrahydrocannabinol and cannabidiol on psychotomimetic symptoms and memory function.Translational psychiatry · 2018Trial
- Influence of cannabis potency on mental health outcomes among adolescents and young adults: scoping review.BJPsych open · 2026Review
- Sex differences in the acute effects of cannabis: the need for hypothesis-driven research.Journal of psychiatry & neuroscience : JPN · 2026Article
- Review
- Assessing rates and predictors of cannabis-associated psychotic symptoms across observational, experimental and medical research.Nature. Mental health · 2024Article
- Cannabis Pharmacogenomics: A Path to Personalized Medicine.Current issues in molecular biology · 2023Review
- Risk factors for cannabis use disorders and cannabis psychosis in Japan: Second report of a survey on cannabis-related health problems among community cannabis users using social networking services.Neuropsychopharmacology reports · 2023Article
- Aberrant salience in cannabis-induced psychosis: a comparative study.Frontiers in psychiatry · 2023Article
- Genetic Variations ofRisk management and healthcare policy · 2023Article
- Cannabis use selectively modulates circulating biomarkers in the blood of schizophrenia patients.Addiction biology · 2022Article
- Rates and correlates of cannabis-associated psychotic symptoms in over 230,000 people who use cannabis.Translational psychiatry · 2022Article
- Article
- Anxiety and cognitive-related effects of ΔPsychopharmacology · 2022Article
- Epigenetic Mediation ofBrain sciences · 2021Article
- Reversing the Psychiatric Effects of Neurodevelopmental Cannabinoid Exposure: Exploring Pharmacotherapeutic Interventions for Symptom Improvement.International journal of molecular sciences · 2021Review
- Effects of Cannabis on Cardiovascular System: The Good, the Bad, and the Many Unknowns.Medical cannabis and cannabinoids · 2021Review
- Pharmacogenetic-guided cannabis usage in the community pharmacy: evaluation of a pilot program.Journal of cannabis research · 2020Article
- Do AKT1, COMT and FAAH influence reports of acute cannabis intoxication experiences in patients with first episode psychosis, controls and young adult cannabis users?Translational psychiatry · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Smoking cannabis daily doubles an individual's risk of developing a psychotic disorder, yet indicators of specific vulnerability have proved largely elusive. Genetic variation is one potential risk modifier. Single-nucleotide polymorphisms in the AKT1 and catechol-O-methyltransferase (COMT) genes have been implicated in the interaction between cannabis, psychosis and cognition, but no studies have examined their impact on an individual's acute response to smoked cannabis. A total 442 healthy young cannabis users were tested while intoxicated with their own cannabis-which was analysed for delta-9-tetrahydrocannbinol (THC) and cannabidiol content-and also ± 7 days apart when drug-free. Psychotomimetic symptoms and working memory were assessed on both the sessions. Variation at the rs2494732 locus of the AKT1 gene predicted acute psychotic response to cannabis along with dependence on the drug and baseline schizotypal symptoms. Working memory following cannabis acutely was worse in females, with some suggestion of an impact of COMT polymorphism on working memory when drug-free. These findings are the first to demonstrate that AKT1 mediates the acute response to cannabis in otherwise healthy individuals and implicate the AKT1 pathway as a possible target for prevention and treatment of cannabis psychosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.